Published in
American Society of Hematology, Blood, 20(125), p. 3144-3152, 2015
DOI: 10.1182/blood-2015-01-621631
Links
- ORCID
- American Society of Hematology | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Journal article published in 2015 by
Carolina Schinke,
Orsolya Giricz,
Weijuan Li,
Aditi Shastri,
Shanisha Gordon,
Laura Barreyro,
Tushar Bhagat,
Sanchari Bhattacharyya,
Nandini Ramachandra,
Matthias Bartenstein 
,
Andrea Pellagatti,
Jacqueline Boultwood,
Amittha Wickrema,
Yiting Yu,
Britta Will
and other authors.
,
Andrea Pellagatti,
Jacqueline Boultwood,
Amittha Wickrema,
Yiting Yu,
Britta Will
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points IL8-CXCR2 is overexpressed in purified stem cells from AML and MDS, and CXCR2 expression is associated with worse prognosis. Inhibition of CXCR2 by genetic and pharmacologic means leads to decreased viability in AML/MDS stem cells and in vitro and in vivo models.